See Today's Golden Star Stocks 🔥 Free for 7 Days See Today's Golden Star Stocks 🔥 Free for 7 Days

News Digest / StockInvest.us

Author: StockInvest.us

11:03am, Wednesday, Aug 13, 2025

Dogwood Therapeutics begins Phase 2b Halneuron dosing; interim Q4 2025, cash to Q1 2026

Dogwood Therapeutics, Inc. (NASDAQ: VIRI) - Quick read: What's happening inside - Status: Pre‑revenue development-stage biopharma. Halneuron® (TTX NaV1.7 program) is lead asset; Phase 2b HALT‑CINP‑203 dosing commenced in Q1 2025. Interim analysis planned Q4 2025; topline expected H2 2026. - Rece...

11:02am, Wednesday, Aug 13, 2025

Agape ATP raises $23M for green energy push; revenue up, margins down, losses and control risks

A

11:01am, Wednesday, Aug 13, 2025

Wright Investors' Service: Cash-Rich Shell Faces Losses, Board Weighs Strategic Options

I

10:07am, Wednesday, Aug 13, 2025

Loar Q2: Revenue up 26.9%, margins and cash improve; watch large goodwill and deal leverage

L

10:06am, Wednesday, Aug 13, 2025

Tecogen ramps product shipments, revenue up 54% but losses persist; $18.2M equity raise

10:06am, Wednesday, Aug 13, 2025

Connect Biopharma starts Phase 2, awaits Simcere China NDA amid revenue cliff

10:05am, Wednesday, Aug 13, 2025

Nucor Q2: Shipments up 8% and sales rise, but earnings, margins and cash drop amid heavy capex

10:04am, Wednesday, Aug 13, 2025

BiomX advances two phage programs; BX004 Phase 2b underway, cash-runway and funding risk

10:02am, Wednesday, Aug 13, 2025

Sanara posts strong revenue and 92% gross margin but higher debt, losses as it builds THP

10:01am, Wednesday, Aug 13, 2025

Neonode Q2: Revenue Falls, Wider Losses Despite 99% Gross Margins; Cash Runway ~12 Months

10:00am, Wednesday, Aug 13, 2025

International Isotopes posts growth, strong margins but still loss‑making; $12.5M sale contingent

09:12am, Wednesday, Aug 13, 2025

Artelo advances Phase 2 amid heavy financings, SOL treasury and going-concern warning

09:11am, Wednesday, Aug 13, 2025

Indaptus advances Decoy20 combo trial but faces heavy cash burn, limited Q4 2025 runway

09:10am, Wednesday, Aug 13, 2025

Worksport surges sales and margins but faces cash burn, going-concern and dilution risks

09:09am, Wednesday, Aug 13, 2025

Ovid trims costs, gets Marinus cash but warns of funding shortfall and Nasdaq delist risk

«
1
2
...
47
48
49
50
51
52
53
...
296
297
»